Alert

Alert Pro Chart

VivoSim Labs Inc. (VIVS)

NasdaqCM: VIVS · Real-Time Price · USD

0.33

-0.02 (-5.71%)

At close: Aug 12, 2026, 3:59 PM

0.34

+1.75%

After-hours: 4:47 PM

-5.71% (1D)

Bid	0.28
Market Cap	1.16M
Revenue (ttm)	131K
Net Income (ttm)	-13.84M
Beta	1.47
EPS (ttm)	-5.35
PE Ratio (ttm)	n/a
Forward PE	n/a
P/B (ttm)	0.20
P/S (ttm)	8.86
Earnings Date	n/a

Ask	0.38
Volume	2,098,223
Avg. Volume (20D)	5,491,885
Open	0.35
Previous Close	0.35
Day's Range	0.33 - 0.35
52-Week Range	0.31 - 5.30
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About VIVS

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissu...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 14, 2012

Employees 9

Stock Exchange NasdaqCM

Ticker Symbol VIVS

Website https://vivosim.ai

Full Company Profile

Financial Performance

In 2026, VivoSim Labs's revenue was 131K, a decrease of -9.03% compared to the previous year's 144K. Earnings were -13.84M, an increase of 456.39%.

Financial Statements

Earnings Surprise

VivoSim Labs has released their quarterly earnings on Feb 19, 2025:

Revenue of $40K misses estimates by $0, with -21.57% YoY decline.

EPS of -2.28 exceeds estimates by 0.12, with 52.50% YoY growth.

News

3 weeks ago · InvestorsHub

VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)

The company’s initial commercial programs in mainland China expand its geographic reach and mark a new step in the global rollout of its human tissue-based drug testing platform. Key Investor Takeaway...

4 weeks ago · InvestorsHub

VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth

The milestone payment strengthens VivoSim’s cash position while management projects significant revenue growth driven by expanding demand for its human-based preclinical testing platform. Key Investor...

6 months ago · GuruFocus.com

NIO January Deliveries Nearly Double Year On Year

EV maker opens 2026 with strong momentum

6 months ago · MT Newswires

Top Midday Gainers

VivoSim Labs (VIVS) said late Thursday it signed agreements appointing JCBio as its distributor in S

6 months ago · Associated Press Finance

BC-Most Active Stocks

GCL Global Holdings Ltd. 49,480,730 1.29

Page 1 of 2

VivoSim Labs Inc. (VIVS)